Liraglutide Injection

Chemical Composition: 
Liraglutide is a long-acting GLP-1 analog with a fatty acid side chain that allows it to bind to albumin, prolonging its action in the bloodstream. This structural modification makes it suitable for once-daily subcutaneous administration.
Mechanism of Action: 
By activating the GLP-1 receptor, Liraglutide stimulates insulin release in the presence of elevated blood glucose levels, suppresses inappropriately high glucagon secretion, and delays gastric emptying to decrease appetite and food intake. Its actions mimic the natural physiological postprandial response, contributing to improved glycemic control and weight reduction.
Indications and Usage: 
Liraglutide is approved for the treatment of type 2 diabetes mellitus to improve glycemic control in adults, as part of a diet and exercise program. It is also indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.
Administration and Dosage: 
Administered via subcutaneous injection, the dosage of Liraglutide is typically initiated at a lower dose to reduce gastrointestinal side effects, then gradually increased to the effective dose. The exact dosage and administration schedule depend on the individual's condition and response to treatment.
Efficacy and Outcomes: 
Clinical trials have shown that Liraglutide significantly improves HbA1c levels in patients with type 2 diabetes and promotes weight loss in patients with obesity when combined with diet and exercise.
Side Effects: 
Common side effects include nausea, diarrhea, vomiting, decreased appetite, and a risk of developing pancreatitis. Injection site reactions are also possible.
Contraindications and Precautions: 
Liraglutide should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Caution is advised in patients with a history of pancreatitis.